Abstract
Since the extensive use of abciximab, a potent antiplatelet agent directed against GP IIb/IIIa platelet receptors, to prevent ischemic complications of percutaneous transluminal coronary angioplasty, few cases of thrombocytopenia have been observed. This paper reports a case of acute profound thrombocytopenia (platelet count: 800/mm3) occurring 16 h after abciximab therapy during coronary angioplasty. As thrombocytopenia occurrence is not predictable, platelet count should be evaluated periodically after drug administration. Mechanisms of this adverse effect remain unknown. Platelet transfusion results in a rapid and sustained improvement of platelet count, avoiding the occurrence of major hemorrhagic complications.
Keywords: abciximab, angioplasty, thrombocytopenia
Full Text
The Full Text of this article is available as a PDF (201.3 KB).
References
- 1. The EPIC Investigators : Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high‐risk coronary angioplasty. N Engl J Med 1994; 330: 956–961 [DOI] [PubMed] [Google Scholar]
- 2. The CAPTURE Investigators : Randomized placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435 [PubMed] [Google Scholar]
- 3. The EPILOG Investigators : Platelet glycoprotein Iib/iiia receptor blockade and low‐dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696 [DOI] [PubMed] [Google Scholar]
- 4. Coller BS: GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemostas 1997; 78: 730–735 [PubMed] [Google Scholar]
- 5. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP: Abciximab‐associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78: 1161–1163 [DOI] [PubMed] [Google Scholar]
- 6. Berkowitz SD, Harrington RA, Rund RN, Tcheng JE: Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809–813 [DOI] [PubMed] [Google Scholar]
- 7. Bednar B, Bednar RA, Cook JJ, Bollag DM, Chang CT, Gaul SL, McQueeney PA, Egbertson MS, Hartman GD, Holahan MA, Lynch JJ, Gould RJ: Drug‐dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation 1996; 94 (suppl I): I–98 [Google Scholar]
- 8. Aster RH: Heparin‐induced thrombocytopenia. N Engl J Med 1995; 332: 1374–1376 [DOI] [PubMed] [Google Scholar]
- 9. Mak KH, Kottke‐Marchand K, Brooks LM. Apheart KL, Topol EJ: Potential value of platelet GPIIh/IIIa antagonist for treating heparin‐induced thrombocytopenia (HIT). J Am Coll Cardiol 1996; 27: 316A [Google Scholar]
- 10. Page Y, Tardy B, Zeni F, Comtet C, Terrana R. Bertrand JC: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337: 774–776 [DOI] [PubMed] [Google Scholar]